ClinicalTrials.gg
CompletedNCT01107457Updated Sep 24, 2019Results posted

A Study in Participants With Moderate to Severe Psoriasis

A Phase 2 interventional study of Ixekizumab and Placebo in Psoriasis, sponsored by Eli Lilly and Company. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
13th of 22
142 · median 156
Started
2010
the only one that year
Phase 2
Only one
of the 22
Registered
1st of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 13th largest by enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The primary purpose for this study is to help answer the following research questions

  • The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
  • Whether ixekizumab can help participants with Psoriasis.
  • How much ixekizumab should be given to participants.
Read the detailed description

The study is a Phase 2 study with 3 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design, Part B is an optional, open label extension design and Part C is an additional optional extension period with an open-label design(up to approximately 104 weeks). Approximately 125 participants will be randomized to 1 of 4 ixekizumab groups or to placebo (approximately 25 participants per group) in Part A. Participants will be evaluated for treatment efficacy and the primary endpoint will be evaluated at week 12. Between week 20 and week 32, participants with a less than 75% improvement in their Psoriasis Area and Severity Index (PASI) score compared to baseline will be eligible to begin Part B. Participants in Part B will receive subcutaneous (SC) injections of ixekizumab 120 milligrams (mg) every 4 weeks through week 236. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236. Participants in Part C may receive SC injections of ixekizumab 80 mg every 4 weeks for up to an additional 104 weeks through approximately week 340. Participants who complete Part A, Part B, and Part C will have a total study participation of approximately 344 weeks.

03

Conditions studied

  • Psoriasis

Keywords

  • Moderate
  • Severe
  • Plaque
  • Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Common to Both Part A:

  • Participant must have active plaque psoriasis covering at least 10% body surface area and a PASI score of at least 12 at screening and at randomization.
  • Participant is a candidate for systemic therapy
  • Participant has a Static Physician's Global Assessment (sPGA) score of at least 3 at screening and at randomization

Inclusion Criterion Specific to Part B

  • Participant has completed the treatment period for part A (at least through week 20)

Inclusion Criterion Specific to Part C

  • Participant has completed the treatment period for part B

Exclusion Criteria Common to Part A, B and C:

  • Participant has pustular, erythrodermic and/or guttate forms of psoriasis
  • Participant has had a flare of psoriasis during the 12 weeks prior to study entry
  • Participant has recently used any biologic agent/monoclonal antibody within the following : etanercept >28 days, infliximab or adalimumab >56 days, alefacept >60 days, ustekinumab >8 months, or any other biologic agent/monoclonal antibody >5 half-lives prior to baseline
  • Participant has received systemic psoriasis therapy (such as psoralen and ultraviolet A [PUVA] light therapy, cyclosporine, , methotrexate, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine) or phototherapy (including ultraviolet B or self-treatment with tanning beds) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization (exception: class 6 [mild, such as desonide] or 7 [least potent, such as hydrocortisone] topical steroids will be permitted for use limited to the face, axilla, and/or genitalia)
  • Participant has donated more than 500 mL of blood within the last month
  • Participant has another serious disorder or illness
  • Participant has suffered a serious bacterial infection (for example, pneumonia, and cellulitis) within the last 3 months
  • Participant has a history of uncontrolled high blood pressure
  • Participant has clinical laboratory test results at entry that are outside the normal reference range
  • Participant is currently participating in or were discontinued within the last 30 days from another clinical trial involving an drug
  • Participant is a woman who is lactating or breast feeding
  • If a participant is a woman and could become pregnant during this study, she must talk to the study doctor about the that you will use to avoid getting pregnant during the study
  • If a participant is post menopausal woman, she must be at least 45 years of age and have not menstruated for the last 12 months
  • If a participant is a woman between 40-45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, she must have an additional blood test to see if you can participate
  • If the participant is male, he must agree to reduce the risk of female partner becoming pregnant during the study

Exclusion Criteria Specific to B:

  • If a participant experienced a serious adverse event during Part A considered possibly related to ixekizumab
  • If a participant experienced an adverse event during Part A that the study doctor believes continued ixekizumab treatment could cause harm to the participant.

Exclusion Criteria Specific to C:

  • If a participant experienced a Serious Adverse Event during Part B considered possibly related to ixekizumab
  • If a participant experienced an adverse event during Part B that the study doctor believes continued ixekizumab treatment could cause harm to the participant.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    10 mg Ixekizumab

    Part A: 10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.

    Biological: Ixekizumab

  • Experimental
    25 mg Ixekizumab

    Part A: 25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.

    Biological: Ixekizumab

  • Experimental
    75 mg Ixekizumab

    Part A: 75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.

    Biological: Ixekizumab

  • Experimental
    150 mg Ixekizumab

    Part A: 150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.

    Biological: Ixekizumab

  • Placebo comparator
    Placebo

    Part A: Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.

    Biological: Ixekizumab · Drug: Placebo

  • Experimental
    120 mg Ixekizumab

    Part B: (optional) 120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236. Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.

    Biological: Ixekizumab

  • Experimental
    80 mg Ixekizumab

    Part B: (optional) Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.

    Biological: Ixekizumab

Interventions

  • BiologicalIxekizumab

    Administered subcutaneously

    Also known as: LY2439821

  • DrugPlacebo

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Week 12

  2. Percentage of PASI Improvement From Baseline to 12 Week Endpoint

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Least squares (LS) mean values were calculated using mixed model repeated measures (MMRM) and controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 12

    The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6 point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

    Time frame: Week 12

  2. Number of Participants With Treatment Emergent Adverse Events Up to 20 Weeks

    Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline Up to 20 Weeks

  3. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 16

    The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal. LS mean was calculated using the analysis of covariance (ANCOVA) model including treatment as fixed effect and baseline as covariate.

    Time frame: Baseline, Week 16

  4. Change From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16

    The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Patient Global Assessment (PatGA) at Week 12

    The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, 12 Weeks

  6. Change From Baseline in Pain Visual Analog Scale (VAS) at Week 12

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used. Least Squares (LS) Mean values were calculated using MMRM and were controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-S) at Week 16

    MOS-S provides a concise assessment of important dimensions of sleep, including initiation, maintenance, respiratory problems, quantity, perceived adequacy, and somnolence during the past 4 weeks. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100,with higher scores for more impairment); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = higher scores indicate greater problems with the attribute.The LS Mean (no multiplicity adjustments) was calculated using an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, Week 16

  8. Number of Participants Who Received Medical Care Measured by Medical Care Resource Utilization (PMRU))

    The PMRU is a 3-item participant-reported questionnaire on health care resource utilization due to psoriasis for physician/clinic visits, emergency room visits, and inpatient hospital admissions since the last study visit.

    Time frame: Week 16

  9. Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI Q) at Week 16

    The WPAI questionnaire has six questions to assess whether the participant was currently employed (Q1); how many hours from work were missed due to problems associated with psoriasis (Q2) or any other reason (Q3); hours actually worked (Q4); degree that psoriasis affected productivity while working (Q5); and degree that psoriasis affected regular activities (Q6) over the past 7 days. Four separate overall scores were calculated, Absenteeism (work time missed) = (Q2/(Q2+Q4))\*100, Presenteeism(impairment at work/reduced on-the-job effectiveness) = (Q5/10) \*100, Work productivity loss(overall work impairment /absenteeism plus presenteeism) = (Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]) \* 100 and Activity Impairment = (Q6/10) \* 100. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity ( worse outcomes). The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Medical Outcomes Study Short-Form 36 (SF-36) - Physical Component Score (PCS) and Mental Component Score (MCS) at Week 16

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. The recall period was the past 4 weeks. The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 12

    The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12

    The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.

    Time frame: Baseline, Week 12

  13. Change From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12

    The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 12

  14. Ixekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks)

    The population pharmacokinetic (PK) modeling value for systemic clearance was based on data from week 1 to week 32 for all participants in all ixekizumab treatment arms.

    Time frame: Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32

  15. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16

    The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. The LS Mean(no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

    Time frame: Baseline, Week 16

  16. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

    PASI combines the extent of body surface involvement in 4 anatomical regions(head,trunk,arms,and legs).For each region the percent area of skin involved was estimated from 0(0%) to 6(90%-100%) and severity was estimated by clinical signs of erythema,induration and scaling with a scores range from 0(none) to 4(very severe).Each area is scored by itself and the scores were then combined for the final PASI.Final PASI calculated as:sum of severity parameters for each region\*area score\*weighing factor (head\[0.1\],upper limbs\[0.2\],trunk\[0.3\],lower limbs \[0.4\]).Overall scores range from 0(no psoriasis) to 72(most severe disease).The LS mean are presented for each treatment versus placebo comparison at each visit and use ANCOVA model including baseline PASI covariate and treatment as fixed effect in the model.Results at Week 12 are summarized as Improvement in PASI which is defined as a reduction in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.

    Time frame: Baseline, Week 12

  17. Percentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75)

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Week 32

  18. Percentage of PASI Improvement From Baseline Through 32 Weeks

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Improvement in PASI is defined as improvement in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.

    Time frame: Baseline Through 32 Weeks

  19. Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement

    The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

    Time frame: Week 32

  20. Percentage of Participants With Anti-Ixekizumab Antibodies

    Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline through Week 20

  21. Percentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1)

    The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

    Time frame: Baseline Up to 240 Weeks

  22. Number of Treatment Emergent Adverse Events up to 344 Weeks

    Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline Up to 344 Weeks

  23. Change From Baseline in Hospital Anxiety and Depression Scale (HADS)

    The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal.

    Time frame: Baseline Up to 240 Weeks

  24. Number of Participants With Patient's Global Assessment of Disease Activity (PatGA)

    The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).

    Time frame: Week 240

  25. Change From Baseline in Pain Visual Analog Scale (VAS)

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used.

    Time frame: Baseline Up to 240 Weeks

  26. Change From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis

    The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. Baseline is defined as the last available value prior to the first dose in Part A of the study.

    Time frame: Baseline Up to 240 Weeks

  27. Change From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis

    The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis. Baseline is defined as the last available value prior to the first dose in Part A of the study.

    Time frame: Baseline Up to 240 Weeks

  28. Change From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis

    The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.

    Time frame: Baseline Up to 240 Weeks

  29. Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Week 240

  30. Change From Baseline in Dermatology Life Quality Index (DLQI)

    The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. Baseline is defined as the last available value prior to the first dose in Part A of the study.

    Time frame: Baseline Up to 240 Weeks

07

Results

Posted Jul 25, 2017

Participant flow

This study has 3 parts:Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging design (approximately 20-40 weeks \[wks\]).Treatment durability (sustained efficacy off treatment) from Week 20 up to Week 32 was evaluated during Part A.

Part A
Participant flow — Part A
MilestonePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab120 mg/80 mg Total Ixekizumab
Started27283029280
Received at least 1 dose of study drug27283029280
Completed22212926270
Not completed571310
Withdrew: Adverse event121000
Withdrew: Withdrawal by subject330310
Withdrew: Lost to follow-up010000
Withdrew: Lack of efficacy100000
Withdrew: Protocol violation010000
Part B and C
Participant flow — Part B and C
MilestonePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab120 mg/80 mg Total Ixekizumab
Started00000120
Completed part b (week 240)0000074
Completed part c000000
Post treatment safety visits000006
Completed000000
Not completed00000120
Withdrew: Adverse event0000012
Withdrew: Inclusion/exclusion criteria not met000001
Withdrew: Physician decision000003
Withdrew: Lack of efficacy000007
Withdrew: Lost to follow-up0000010
Withdrew: Protocol violation000001
Withdrew: Sponsor decision0000066
Withdrew: Withdrawal by subject0000016
Withdrew: Clinical relapse000004

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement
percentage of participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement7.728.676.782.882.1
Statistical analysis
  • Placebo vs 10 mg Ixekizumab · Fisher Exact · p = 0.079
  • Placebo vs 25 mg Ixekizumab · Fisher Exact · p = <0.001
  • Placebo vs 75 mg Ixekizumab · Fisher Exact · p = <0.001
  • Placebo vs 150 mg Ixekizumab · Fisher Exact · p = <0.001
PrimaryPercentage of PASI Improvement From Baseline to 12 Week Endpoint

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Least squares (LS) mean values were calculated using mixed model repeated measures (MMRM) and controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Percentage of improvement in PASI score
Percentage of PASI Improvement From Baseline to 12 Week Endpoint
Percentage of improvement in PASI scorePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of PASI Improvement From Baseline to 12 Week Endpoint16.22 (4.44 to 28.01)49.33 (38.25 to 60.41)78.48 (67.67 to 89.29)85.69 (74.87 to 96.50)87.12 (75.94 to 98.29)
Statistical analysis
  • Placebo vs 10 mg Ixekizumab · Mixed Models Analysis · p = <0.001
  • Placebo vs 25 mg Ixekizumab · Mixed Models Analysis · p = <0.001
  • Placebo vs 75 mg Ixekizumab · Mixed Models Analysis · p = <0.001
  • Placebo vs 150 mg Ixekizumab · Mixed Models Analysis · p = <0.001
SecondaryPercentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 12

The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6 point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 12
percentage of participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 127.725.070.072.471.4
SecondaryNumber of Participants With Treatment Emergent Adverse Events Up to 20 Weeks

Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline Up to 20 Weeks
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events Up to 20 Weeks
ParticipantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Number of Participants With Treatment Emergent Adverse Events Up to 20 Weeks1721211713
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 16

The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal. LS mean was calculated using the analysis of covariance (ANCOVA) model including treatment as fixed effect and baseline as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Anxiety-0.86 ± 0.58-1.97 ± 0.55-2.10 ± 0.54-2.17 ± 0.54-2.81 ± 0.55
Depression0.17 ± 0.54-1.86 ± 0.51-1.75 ± 0.51-2.52 ± 0.51-2.01 ± 0.51
SecondaryChange From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16

The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16-0.49 ± 0.56-1.56 ± 0.52-1.48 ± 0.53-2.13 ± 0.52-2.21 ± 0.54
SecondaryChange From Baseline in Patient Global Assessment (PatGA) at Week 12

The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, 12 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Global Assessment (PatGA) at Week 12
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Patient Global Assessment (PatGA) at Week 12-0.6 ± 0.3-1.1 ± 0.3-2.3 ± 0.2-2.9 ± 0.3-2.5 ± 0.3
SecondaryChange From Baseline in Pain Visual Analog Scale (VAS) at Week 12

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used. Least Squares (LS) Mean values were calculated using MMRM and were controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · millimeter (mm)
Change From Baseline in Pain Visual Analog Scale (VAS) at Week 12
millimeter (mm)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Pain Visual Analog Scale (VAS) at Week 123.87 (-20.90 to 28.64)-4.32 (-23.05 to 14.41)-19.36 (-34.31 to -4.40)-21.24 (-37.89 to -4.58)-34.24 (-51.83 to -16.66)
SecondaryChange From Baseline in Medical Outcomes Study Sleep Scale (MOS-S) at Week 16

MOS-S provides a concise assessment of important dimensions of sleep, including initiation, maintenance, respiratory problems, quantity, perceived adequacy, and somnolence during the past 4 weeks. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100,with higher scores for more impairment); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = higher scores indicate greater problems with the attribute.The LS Mean (no multiplicity adjustments) was calculated using an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-S) at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Sleep Problems Index I-0.05 ± 2.61-5.35 ± 2.46-8.78 ± 2.42-7.97 ± 2.42-2.38 ± 2.47
Sleep Problems Index II0.21 ± 2.37-6.42 ± 2.24-9.23 ± 2.20-8.43 ± 2.20-2.48 ± 2.24
Sleep Adequacy-2.83 ± 4.735.63 ± 4.4711.35 ± 4.398.81 ± 4.39-0.41 ± 4.48
Sleep Disturbance-1.47 ± 3.27-8.56 ± 3.10-10.02 ± 3.03-11.50 ± 3.04-4.67 ± 3.09
Sleep Somnolence1.12 ± 2.73-2.32 ± 2.58-7.14 ± 2.53-5.80 ± 2.53-0.76 ± 2.58
Snoring-2.85 ± 4.22-0.47 ± 3.942.94 ± 3.88-3.24 ± 3.87-3.81 ± 3.94
Sleep Short of Breath/headache4.34 ± 3.10-5.45 ± 2.92-2.84 ± 2.87-2.65 ± 2.87-3.46 ± 2.91
SecondaryNumber of Participants Who Received Medical Care Measured by Medical Care Resource Utilization (PMRU))

The PMRU is a 3-item participant-reported questionnaire on health care resource utilization due to psoriasis for physician/clinic visits, emergency room visits, and inpatient hospital admissions since the last study visit.

Time frame:
Week 16
Reported as:
Number · participants
Number of Participants Who Received Medical Care Measured by Medical Care Resource Utilization (PMRU))
participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Week 16 - Office or Clinic(n=23,24,29,28,27)10013
Week 16 - Emergency Room(ER)(n=23, 24, 29, 28, 27)00001
Week 16 - Admitted thru ER (n=26,28,30,29,28)00000
Week 16 - Hospital Stay (n=26,28,30,29,28)00000
SecondaryChange From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI Q) at Week 16

The WPAI questionnaire has six questions to assess whether the participant was currently employed (Q1); how many hours from work were missed due to problems associated with psoriasis (Q2) or any other reason (Q3); hours actually worked (Q4); degree that psoriasis affected productivity while working (Q5); and degree that psoriasis affected regular activities (Q6) over the past 7 days. Four separate overall scores were calculated, Absenteeism (work time missed) = (Q2/(Q2+Q4))\*100, Presenteeism(impairment at work/reduced on-the-job effectiveness) = (Q5/10) \*100, Work productivity loss(overall work impairment /absenteeism plus presenteeism) = (Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]) \* 100 and Activity Impairment = (Q6/10) \* 100. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity ( worse outcomes). The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI Q) at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Absenteeism (n=15,19,14,19,16)-1.91 ± 1.880.71 ± 1.68-0.83 ± 1.94-2.64 ± 1.67-1.96 ± 1.82
Presenteeism (n=15,20,16,19,16)-3.38 ± 3.99-0.99 ± 3.47-4.59 ± 3.87-14.48 ± 3.55-10.69 ± 3.90
Work productivity loss (n=15,19,14,19,16)-3.65 ± 4.301.74 ± 3.82-4.65 ± 4.45-14.76 ± 3.82-11.12 ± 4.17
Activity Impairment (n=25,28,28,29,27)-0.68 ± 4.19-9.76 ± 3.96-14.96 ± 3.95-12.81 ± 3.90-14.79 ± 4.03
SecondaryChange From Baseline in Medical Outcomes Study Short-Form 36 (SF-36) - Physical Component Score (PCS) and Mental Component Score (MCS) at Week 16

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. The recall period was the past 4 weeks. The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study Short-Form 36 (SF-36) - Physical Component Score (PCS) and Mental Component Score (MCS) at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
PCS-1.22 ± 2.152.41 ± 2.031.95 ± 2.033.94 ± 2.005.72 ± 2.03
MCS-0.56 ± 2.297.27 ± 2.195.16 ± 2.184.13 ± 2.134.15 ± 2.16
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 12

The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 12
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 122.21 (-5.17 to 9.58)-4.85 (-12.82 to 3.12)-3.65 (-12.73 to 5.43)-15.89 (-24.98 to -6.81)-19.91 (-29.00 to -10.83)
SecondaryChange From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12

The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12-1.0 (-10.3 to 8.3)-6.4 (-12.3 to -0.5)-4.6 (-10.3 to 1.2)-3.4 (-11.5 to 4.8)-12.8 (-20.9 to -4.7)
SecondaryChange From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12

The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12-7.3 (-11.2 to -3.5)-10.2 (-13.9 to -6.6)-15.8 (-19.2 to -12.4)-15.0 (-18.9 to -11.0)-17.2 (-20.8 to -13.7)
SecondaryIxekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks)

The population pharmacokinetic (PK) modeling value for systemic clearance was based on data from week 1 to week 32 for all participants in all ixekizumab treatment arms.

Time frame:
Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32
Reported as:
Mean · liters per hour (L/hr)
Ixekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks)
liters per hour (L/hr)All Participants (10mg, 25mg,75mg & 150 mg Ixekizumab)
Ixekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks)0.0177 (0.0160 to 0.0199)
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16

The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. The LS Mean(no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16-1.24 ± 0.97-6.35 ± 0.92-6.59 ± 0.90-8.39 ± 0.90-8.17 ± 0.92
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

PASI combines the extent of body surface involvement in 4 anatomical regions(head,trunk,arms,and legs).For each region the percent area of skin involved was estimated from 0(0%) to 6(90%-100%) and severity was estimated by clinical signs of erythema,induration and scaling with a scores range from 0(none) to 4(very severe).Each area is scored by itself and the scores were then combined for the final PASI.Final PASI calculated as:sum of severity parameters for each region\*area score\*weighing factor (head\[0.1\],upper limbs\[0.2\],trunk\[0.3\],lower limbs \[0.4\]).Overall scores range from 0(no psoriasis) to 72(most severe disease).The LS mean are presented for each treatment versus placebo comparison at each visit and use ANCOVA model including baseline PASI covariate and treatment as fixed effect in the model.Results at Week 12 are summarized as Improvement in PASI which is defined as a reduction in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
units on a scalePlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 123.50 ± 1.218.20 ± 1.1713.56 ± 1.1214.99 ± 1.1415.38 ± 1.16
SecondaryPercentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75)

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75)
percentage of participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75)050.059.156.582.6
SecondaryPercentage of PASI Improvement From Baseline Through 32 Weeks

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Improvement in PASI is defined as improvement in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.

Time frame:
Baseline Through 32 Weeks
Reported as:
Mean · Percentage PASI improvement
Percentage of PASI Improvement From Baseline Through 32 Weeks
Percentage PASI improvementPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of PASI Improvement From Baseline Through 32 Weeks—80.55 ± 17.6985.60 ± 12.7485.16 ± 15.3088.11 ± 11.35
SecondaryPercentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement

The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement
percentage of participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement—33.345.547.865.2
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline through Week 20
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
percentage of participantsPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg Ixekizumab
Percentage of Participants With Anti-Ixekizumab Antibodies4.054.240.017.222.2
SecondaryPercentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1)

The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1)
percentage of participantsTotal Ixekizumab (80 mg and 120 mg)
Percentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1)78.4
SecondaryNumber of Treatment Emergent Adverse Events up to 344 Weeks

Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline Up to 344 Weeks
Reported as:
Count of participants · Participants
Number of Treatment Emergent Adverse Events up to 344 Weeks
ParticipantsTotal Ixekizumab (80 mg and 120 mg)
Number of Treatment Emergent Adverse Events up to 344 Weeks105
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS)

The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS)
units on a scaleTotal Ixekizumab (80 mg and 120 mg)
Anxiety-3.0 ± 3.4
Depression-2.8 ± 3.0
SecondaryNumber of Participants With Patient's Global Assessment of Disease Activity (PatGA)

The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).

Time frame:
Week 240
Reported as:
Count of participants · Participants
Number of Participants With Patient's Global Assessment of Disease Activity (PatGA)
ParticipantsTotal Ixekizumab (80 mg and 120 mg)
0(Clear)40
126
24
32
42
5(Severe)0
SecondaryChange From Baseline in Pain Visual Analog Scale (VAS)

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · Millimeters (mm)
Change From Baseline in Pain Visual Analog Scale (VAS)
Millimeters (mm)Total Ixekizumab (80 mg and 120 mg)
Change From Baseline in Pain Visual Analog Scale (VAS)-13.25 ± 32.34
SecondaryChange From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis

The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. Baseline is defined as the last available value prior to the first dose in Part A of the study.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · units on a scale
Change From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis
units on a scaleTotal Ixekizumab (80 mg and 120 mg)
Change From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis-33.62 ± 30.48
SecondaryChange From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis

The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis. Baseline is defined as the last available value prior to the first dose in Part A of the study.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · units on a scale
Change From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis
units on a scaleTotal Ixekizumab (80 mg and 120 mg)
Change From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis-19.89 ± 13.68
SecondaryChange From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis

The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · units on a scale
Change From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis
units on a scaleTotal Ixekizumab (80 mg and 120 mg)
Change From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis-9.10 ± 7.59
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

Time frame:
Week 240
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement
percentage of participantsTotal Ixekizumab (80 mg and 120 mg)
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement97.3
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI)

The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. Baseline is defined as the last available value prior to the first dose in Part A of the study.

Time frame:
Baseline Up to 240 Weeks
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI)
units on a scaleTotal Ixekizumab (80 mg and 120 mg)
Change From Baseline in Dermatology Life Quality Index (DLQI)-9.2 ± 5.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/27 (3.7%)13/27 (48.1%)
10 mg Ixekizumab—1/28 (3.6%)15/28 (53.6%)
25 mg Ixekizumab—1/30 (3.3%)12/30 (40%)
75 mg Ixekizumab—0/29 (0%)10/29 (34.5%)
150 mg Ixekizumab—0/28 (0%)11/28 (39.3%)
Treatment Durability—1/74 (1.4%)11/74 (14.9%)
120 mg and 80 mg Total Ixekizumab—24/120 (20%)82/120 (68.3%)
Post Treatment Safety Visits—0/6 (0%)1/6 (16.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTreatment Durability120 mg and 80 mg Total IxekizumabPost Treatment Safety Visits
DysmenorrhoeaReproductive system and breast disorders1/130/120/120/100/140/330/500/4
Mitral valve prolapseCardiac disorders0/271/280/300/290/280/741/1200/6
NephrolithiasisRenal and urinary disorders0/270/281/300/290/281/742/1200/6
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/120/120/100/140/331/500/4
Abortion missedPregnancy, puerperium and perinatal conditions0/130/120/120/100/140/331/500/4
Acute coronary syndromeCardiac disorders0/270/280/300/290/280/741/1200/6
Arteriosclerosis coronary arteryCardiac disorders0/270/280/300/290/280/741/1200/6
Atrial fibrillationCardiac disorders0/270/280/300/290/280/741/1200/6
Cardiac failure congestiveCardiac disorders0/270/280/300/290/280/741/1200/6
Pancreatitis acuteGastrointestinal disorders0/270/280/300/290/280/741/1200/6
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlacebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTreatment Durability120 mg and 80 mg Total IxekizumabPost Treatment Safety Visits
NasopharyngitisInfections and infestations5/273/283/303/294/282/7429/1200/6
HypersensitivityImmune system disorders1/271/280/300/290/280/740/1201/6
HeadacheNervous system disorders1/274/284/301/291/283/7412/1200/6
SinusitisInfections and infestations1/270/280/301/290/281/7417/1200/6
Upper respiratory tract infectionInfections and infestations1/271/283/301/291/280/7415/1200/6
Urinary tract infectionInfections and infestations0/271/281/300/291/282/7413/1200/6
Injection site reactionGeneral disorders0/270/283/301/292/280/744/1200/6
Tooth infectionInfections and infestations0/271/280/301/290/280/7411/1200/6
BronchitisInfections and infestations0/271/280/300/290/280/7410/1200/6
DiarrhoeaGastrointestinal disorders0/271/280/301/291/280/749/1200/6

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
Mean45 ± 12.7647.65 ± 11.2045.93 ± 14.5346.37 ± 12.5045.97 ± 13.0046.19 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
Female131212101461
Male141618191481
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
Hispanic or Latino5574425
Not Hispanic or Latino2223232524117
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
American Indian or Alaska Native001102
Asian010214
Native Hawaiian or Other Pacific Islander000000
Black or African American201227
White2527282425129
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
United States2727292828139
Denmark011103
Baseline in Psoriasis Area and Severity Index (PASI)
Baseline in Psoriasis Area and Severity Index (PASI)(units on a scale)Placebo10 mg Ixekizumab25 mg Ixekizumab75 mg Ixekizumab150 mg IxekizumabTotal
Mean16.45 ± 5.2619.18 ± 7.9618.55 ± 4.9417.20 ± 4.2617.70 ± 6.2117.83 ± 5.85
08

Study locations

34 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Haven, Connecticut 06511, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20037, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33175, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miramar, Florida 33027, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newnan, Georgia 30263, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington Heights, Illinois 60005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Skokie, Illinois, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Dundee, Illinois 60118, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Bend, Indiana 46617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reno, Nevada 89511, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jamaica, New York 11418, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10029, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14623, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stony Brook, New York 11790, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveland, Ohio 44106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Oswego, Oregon 97035, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97223, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37922, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37215, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    College Station, Texas 77845, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norfolk, Virginia 23507, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23294, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aarhus, 8000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hellerup, 2900, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kobenhavn, 2400, Denmark
09

References and documents

Publications

  • Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, Zhu B, Wei H, Cameron GS, Heffernan MP. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1763-70. doi: 10.1111/jdv.12996. Epub 2015 Feb 18. PubMed 25693783 ↗
  • Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19. PubMed 25242558 ↗
  • Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997. PubMed 22455413 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jan 2011 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 6 years 6 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2010
First posted
Apr 21, 2010
Start
Apr 2010
Primary completionActual
Jan 2011
CompletionActual
Jul 2016
Results delay requested
Apr 5, 2011
Results first posted
Jul 25, 2017
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01107457
Responsible party
Sponsor
First posted
Apr 21, 2010
Start date
Apr 2010
Primary completion
Jan 2011
Completion
Jul 2016
Results posted
Jul 25, 2017
Last update
Sep 24, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion